Clinical Study
Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
Table 1
Patient characteristics.
| | Characteristics | |
| | Median age, years (range) | 46 (20–58) | | Male gender, n (%) | 16 (62%) | | Median BMI (range) | 28.2 (18.4–39.6) | | AML diagnosis, n (%) | | | (i) De novo | 23 (88%) | | (ii) Treatment-related | 3 (12%) | | Prior MDS, n (%) | 3 (12%) | | ECOG performance status, median (range) | 1 (0–2) | | Disease status, n (%) | | | (i) Refractory | 18 (69%) | | (ii) Relapsed | 8 (31%) | | Prior therapies, median (range) | 1 (1–4) | | Prior treatments | | | 7 + 3 | 23 (88%) | | HiDAC | 8 (31%) | | Etoposide/mitoxantrone | 2 (8%) | | Prior allo-HCT, n (%) | 2 (8%) | | Genetic risk group [3], n (%) | | | Favorable | 5 (19%) | | Intermediate I | 10 (39%) | | Intermediate II | 6 (23%) | | Poor risk | 5 (19%) |
|
|
BMI: body mass index, AML: acute myeloid leukemia, MDS: myelodysplastic syndromes, ECOG: Eastern Cooperative Oncology Group, 7 + 3: cytarabine + anthracycline chemotherapy, HiDAC: high-dose cytarabine, and HCT: hematopoietic cell transplant.
|
